Literature DB >> 6430285

Structure elucidation of platelet activating factor derived from human neutrophils.

K L Clay, R C Murphy, J L Andres, J Lynch, P M Henson.   

Abstract

Platelet activating factor (PAF) synthesized by human neutrophils challenged by opsonized zymosan or calcium ionophore was isolated from cells and buffer using Bligh and Dyer extraction following the addition of tracer amounts of tritiated-PAF. The extract was subjected to TLC separation of phospholipid classes, followed by reverse phase HPLC for molecular species separation. All fractions were measured for radioactivity, biological activity and fast atom bombardment mass spectrometry. While the radioactive tracer PAF could be separated into three molecular species, PAF biological activity eluted as a single component which was characterized as 1-O-hexadecyl-2-acetyl-glycero-3-phosphocholine. The lack of molecular species heterogeneity of PAF produced in response to stimuli implies a higher degree of control of biosynthesis than previously suspected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430285     DOI: 10.1016/0006-291x(84)90751-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Cellular and humoral mediators of pulmonary edema.

Authors:  A B Malik; W M Selig; K E Burhop
Journal:  Lung       Date:  1985       Impact factor: 2.584

Review 2.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 3.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

4.  1-Acyl-2-acetyl-sn-glycero-3-phosphocholine from stimulated human polymorphonuclear leukocytes.

Authors:  K Satouchi; M Oda; K Saito
Journal:  Lipids       Date:  1987-04       Impact factor: 1.880

5.  Interaction of platelet-activating factor with cultured guinea pig tracheal epithelial cells.

Authors:  L Churchill; F H Chilton; D Proud
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

6.  Potential phospholipid source(s) of arachidonate used for the synthesis of leukotrienes by the human neutrophil.

Authors:  F H Chilton
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857

7.  Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

Authors:  R M Barr; F Lawlor; M R Judge; P Courtney; R Barlow; A Kobza Black; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

8.  The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

Authors:  Friederike K Keating; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

9.  Dynamics of platelet-activating-factor release and uptake in a human neutrophil suspension.

Authors:  M Cluzel; C A Rohde; D W MacGlashan; B J Undem; F H Chilton
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

10.  Platelet activating factor (PAF) and lyso-PAF in psoriasis.

Authors:  M R Judge; R M Barr; A I Mallet; F Courtney; A Kobza Black; M W Greaves
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.